Quick Answer
NovoCure Ltd reported Net Income Loss of -$136.23 million for the year ending 2025.
- NovoCure Ltd showed an increase of +19.2% in Net Income Loss from 2024 to 2025.
- This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$11.69 million | Q4 2018: -$15.63 million | Q1 2019: -$12.15 million | Q2 2019: -$1.27 million | Q3 2019: $1.93 million | Q4 2019: $4.26 million | Q1 2020: $3.95 million | Q2 2020: $1.66 million | Q3 2020: $9.28 million | Q4 2020: $4.92 million | Q1 2021: -$4.13 million | Q2 2021: -$14.64 million | Q3 2021: -$13.12 million | Q4 2021: -$26.46 million | Q1 2022: -$4.65 million | Q2 2022: -$24.01 million | Q3 2022: -$26.58 million | Q4 2022: -$37.30 million | Q1 2023: -$53.06 million | Q2 2023: -$57.42 million | Q3 2023: -$49.49 million | Q1 2024: -$38.76 million | Q2 2024: -$33.38 million | Q3 2024: -$30.57 million | Q1 2025: -$34.32 million | Q2 2025: -$40.14 million | Q3 2025: -$37.27 million.
- Over the full 13 years of available data (2013 to 2025), NovoCure Ltd's Net Income Loss has declined by 76.1%.
- Historical annual values: Fiscal year 2025: -$136.23 million | Fiscal year 2024: -$168.63 million | Fiscal year 2023: -$207.04 million | Fiscal year 2022: -$92.53 million | Fiscal year 2021: -$58.35 million | Fiscal year 2020: $19.81 million | Fiscal year 2019: -$7.23 million | Fiscal year 2018: -$63.56 million | Fiscal year 2017: -$61.66 million | Fiscal year 2016: -$131.85 million | Fiscal year 2015: -$111.58 million | Fiscal year 2014: -$80.68 million | Fiscal year 2013: -$77.37 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: